See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Could Byetta Become a Standalone Drug?

Craig Eberhard

Could Byetta Become a Standalone Drug?

New Small Molecule Drugs for Type 2 - Human Trials Underway

Christoph Westphal, MD, Ph.D

New Small Molecule Drugs for Type 2 - Human Trials Underway

Easy to Use Insulin Delivery Patch

Anna Tucker

Easy to Use Insulin Delivery Patch

Victoza

Page 2
Type 2 Drug Victoza Helps Type 1s, Too
Jul 11, 2011 | 
Victoza, a drug aimed at type 2 diabetes, may turn out to be a boon for type 1 diabetes patients as well. A small clinical study shows that patients with well-controlled type 1 who took Victoza daily for just one week experienced a 15 percent drop in their blood sugar levels. Patients who took the drug over a full 24-week test period needed less and less insulin, decreasing their average mealtime dose by seven units and their all-day insulin requirement by eight.
Sanofi Says Late-Stage Trial of Type 2 Drug a Success
May 23, 2011 | 
French drug maker Sanofi-aventis says that results from a Phase III trial of its experimental type 2 diabetes drug lixisenatide show that the drug successfully lowered patients' blood glucose levels and body weight, but did not increase the risk of hypoglycemia.
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Could Byetta Become a Standalone Drug?

Craig Eberhard

Could Byetta Become a Standalone Drug?

New Small Molecule Drugs for Type 2 - Human Trials Underway

Christoph Westphal, MD, Ph.D

New Small Molecule Drugs for Type 2 - Human Trials Underway

Easy to Use Insulin Delivery Patch

Anna Tucker

Easy to Use Insulin Delivery Patch

FDA Gives Novo the Go-Ahead to Market Victoza® in the U.S.
Feb 27, 2010 | 
Danish pharmaceutical company Novo Nordisk has received Food and Drug Administration permission to begin marketing its type 2 drug Victoza® in the United States.
Victoza, the brand name for liraglutide, is a GLP-1* analog that is taken one a day by injection to help control blood sugar-and in some cases, help with weight loss-in patients with type 2 diabetes.
Novo, Upping the Ante in the Race for an Oral GLP-1 Drug, Tests a Pill Version of Victoza
Feb 1, 2010 | 
Denmark-based Novo Nordisk has begun a Phase 1 trial of a pill form of a GLP-1 drug very similar to its Victoza product. The trial will involve  155 British patients with type 2 diabetes. The test on human subjects, although very early-stage,  puts the company in the lead to develop an oral form of a GLP-1 drug.
Novo Nordisk's Victoza Receives FDA Approval for the Treatment of Type 2 Diabetes
Jan 28, 2010 | 
Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza (liraglutide injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
« Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.